Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying 1 STATEMENT OF THE ALLIANCE FOR PHARMACY COMPOUNDING: UNDERSTANDING LAW AND REGULATION GOVERNING THE COMPOUNDING OF PEPTIDE PROD FDA Peptide Reclassification 2026: What It Means for Providers The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter What is a 503B outsourcing facility, and why are so many of them uninspected by FDA? Partnership for Safe Medicines